(275 days)
The Senographe DS and Senographe Essential FFDM systems generate digital mammographic images that can be used for screening and in the diagnosis of breast cancer. The Senographe DS and Senographe Essential FFDM systems are intended to be used in the same clinical applications as traditional film-based mammographic systems.
Premium View is an image-processing algorithm, which increases the visibility of breast structures. The main advantage is to provide a single breast image, where the contrast in the fatty tissues is similar to that obtained by setting WW (window width) and WL (window level) for optimum visualization of fatty tissues, and the contrast in the fibro-glandular tissue is similar to that obtained by setting WW and WL for optimal visualization of fibro-glandular tissues.
PV i is an option that can simplify the presentation of mammographic images, improve workflow, and streamline the review process of images with very dark or bright areas by presenting the image with the WW and WL optimized for review with minimal need for the user to make adjustments for the various tissue areas. This could be especially useful with patients who have very dense breasts, or implants that currently require multiple adjustments of WW and WL to review.
The Senographe DS and Senographe Essential are both full field digital mammography systems consisting of a digital detector, a dual track x-ray tube (molybdenum / rhodium) and an x-ray generator with control. The digital detector is a flat panel of amorphous silicon on which cesium iodide is deposited to maximize the detection of x-rays. The x-ray filter is a wheel with both a molybdenum and a rhodium filter to allow various combinations of xray tube track and filter when imaging breasts of different radiological densities. The system includes a feature called Automatic Optimization of Parameters (AOP) that automatically selects the kVp, the optimal x-ray tube track and beam filtration and then terminates the exposure based on the breast density to provide consistent image quality for the user across a wide range of breast sizes and densities.
The subject of this submission will introduce a modification to a previously approved (P990066 / S015 and P990066 S020) image processing algorithm called Premium View. Premium View is an image-processing algorithm, which increases the visibility of breast structures. The main advantage is to provide a single breast image, where the contrast in the fatty tissues is similar to that obtained by setting WW (window width) and WL (window level) for optimum visualization of fatty tissues, and the contrast in the fibro-glandular tissue is similar to that obtained by setting WW and WL for optimal visualization of fibro-glandular tissues.
Premium View i, when utilized with the Senographe DS or Senographe Essential introduces a software change that applies different LUT values during the image processing prior to display of a very dense breast, or one with implants. This Premarket Notification will implement this technology on GE Healthcare's existing Full Field Digital Mammography systems as an upgrade to existing systems, or as an option to new installations.
The provided document describes a 510(k) premarket notification for the "Premium View i" (PVi) image processing option for GE Healthcare's Full Field Digital Mammography (FFDM) systems (Senographe DS and Senographe Essential). The document focuses on demonstrating substantial equivalence to predicate devices and describes the intended use and technical aspects of the PVi algorithm. However, it does not contain specific details about acceptance criteria, a formal study proving explicit device performance against those criteria, or quantitative results of such a study.
The document mentions "clinical testing to quantify the clinical acceptance of images that had been retrospectively processed with this image processing algorithm," but it does not provide the results, metrics, sample sizes, expert qualifications, or adjudication methods for this clinical testing.
Therefore, for the information requested, I can only extract what is explicitly stated or can be reasonably inferred from the provided text. Many specific details about the study design and results are missing.
Here's a summary based on the available information:
1. Table of Acceptance Criteria and Reported Device Performance:
The document does not explicitly state specific acceptance criteria in terms of quantitative performance metrics (e.g., sensitivity, specificity, AUC) or provide a table directly comparing these criteria to the device's reported performance.
Instead, the conclusion states: "GE Healthcare considers the Premium View i option to be as safe, as effective, and performance is substantially equivalent to the predicate device(s)." This implies that the 'acceptance criteria' were met by demonstrating substantial equivalence, which is the primary regulatory pathway for 510(k) submissions. However, no specific performance metrics are given.
The closest to "performance" stated is a qualitative description of the algorithm's effect:
"Premium View is an image-processing algorithm, which increases the visibility of breast structures. The main advantage is to provide a single breast image, where the contrast in the fatty tissues is similar to that obtained by setting WW (window width) and WL (window level) for optimum visualization of fatty tissues, and the contrast in the fibro-glandular tissue is similar to that obtained by setting WW and WL for optimal visualization of fibro-glandular tissues."
| Acceptance Criteria (Implied by 510(k) pathway) | Reported Device Performance (Qualitative) |
|---|---|
| Safe | Considered "as safe" as predicate devices |
| Effective | Considered "as effective" as predicate devices |
| Performance substantially equivalent to predicate devices | Performance considered "substantially equivalent" to predicate devices |
| Increases visibility of breast structures | Yes, increases visibility of breast structures |
| Provides single breast image with optimized contrast for fatty and fibro-glandular tissues | Yes, achieves this by applying different LUTs to high pass and low pass extractions, enhancing contrast in glandular tissue while preserving whole breast visibility. |
| Simplifies image presentation and improves workflow, especially for dense breasts or implants | Yes, "can simplify the presentation of mammographic images, improve workflow, and streamline the review process...especially useful with patients who have very dense breasts, or implants." |
2. Sample size used for the test set and data provenance:
- Sample Size for Test Set: Not specified. The document only mentions "clinical testing to quantify the clinical acceptance of images."
- Data Provenance: Retrospective ("retrospectively processed with this image processing algorithm"). The country of origin is not specified.
3. Number of experts used to establish the ground truth for the test set and their qualifications:
- Number of Experts: Not specified.
- Qualifications of Experts: Not specified. The document only refers to "clinical testing" for "clinical acceptance."
4. Adjudication method for the test set:
- Adjudication Method: Not specified.
5. Multi-Reader Multi-Case (MRMC) comparative effectiveness study:
- MRMC Study Done: Not specified. The document does not mention an MRMC study or any comparison of human readers with vs. without AI assistance. The focus is on the image processing algorithm itself.
6. Standalone (algorithm only without human-in-the-loop performance) study:
- Standalone Study Done: Yes, implicitly. The "clinical testing to quantify the clinical acceptance of images that had been retrospectively processed with this image processing algorithm" suggests an evaluation of the algorithm's output (processed images) rather than a human-in-the-loop study comparing diagnostic accuracy. However, no specific performance metrics are provided.
7. Type of ground truth used:
- Type of Ground Truth: Not specified. Given the context of "clinical acceptance of images," it's likely based on radiologists' subjective evaluation of image quality or visibility of structures rather than definitive pathology or outcome data.
8. Sample size for the training set:
- Sample Size for Training Set: Not specified. The document describes the algorithm's functionality and its development processes (risk analysis, requirements reviews, design reviews, various levels of testing) but does not detail the training set size for the algorithm itself. It's possible the algorithm was developed through iterative refinement rather than a single distinct "training set" like in modern deep learning contexts.
9. How the ground truth for the training set was established:
- Ground Truth for Training Set: Not specified. The document outlines general quality assurance measures applied during development but does not detail how ground truth was established for "training" the image processing algorithm.
{0}------------------------------------------------
DEC 22 2011
KI10798
510(k) Summary
In accordance with 21 CFR 807.92 the following summary of information is provided:
| Date: | 03/18/2011 |
|---|---|
| Submitter: | GE Healthcare3000 N. Grandview BlvdMail Code W-709Waukesha, WI 53188 |
| Primary Contact Person: | Steven Kachelmeyer, RACRegulatory ManagerGE Healthcare |
| Phone: | 262-548-2432 |
| Fax: | 262-997-1080 |
| Secondary Contact Person: | David BlonskiX-ray Regulatory Affairs DirectorGE Healthcare |
| Phone: | 262-513-4072 |
| Fax: | 262-544-3844 |
| Device:Trade Name:Common/Usual Name:Classification Names: | Premium View iFull Field Digital Mammography System21 CFR 892.1715, Class II |
| Product Code: | MUE |
| Predicate Device(s): | Senographe DS-P990066/S16,Senographe Essential-P990066/S21 |
| Device Description: | The Senographe DS and Senographe Essential are bothfull field digital mammography systems consisting of adigital detector, a dual track x-ray tube (molybdenum /rhodium) and an x-ray generator with control. The digitaldetector is a flat panel of amorphous silicon on whichcesium iodide is deposited to maximize the detection of x- |
Image /page/0/Picture/9 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'G' and 'E' intertwined within a circular border. The letters are stylized and connected, creating a recognizable monogram.
·
.
{1}------------------------------------------------
Image /page/1/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters "GE" intertwined and enclosed within a circle. There are small decorative elements resembling droplets or flourishes around the outer edge of the circle. The logo is black and white.
rays. The x-ray filter is a wheel with both a molybdenum and a rhodium filter to allow various combinations of xray tube track and filter when imaging breasts of different radiological densities. The system includes a feature called Automatic Optimization of Parameters (AOP) that automatically selects the kVp, the optimal x-ray tube track and beam filtration and then terminates the exposure based on the breast density to provide consistent image quality for the user across a wide range of breast sizes and densities.
The subject of this submission will introduce a modification to a previously approved (P990066 / S015 and P990066 S020) image processing algorithm called Premium View. Premium View is an image-processing algorithm, which increases the visibility of breast structures. The main advantage is to provide a single breast image, where the contrast in the fatty tissues is similar to that obtained by setting WW (window width) and WL (window level) for optimum visualization of fatty tissues, and the contrast in the fibro-glandular tissue is similar to that obtained by setting WW and WL for optimal visualization of fibro-glandular tissues.
Premium View i, when utilized with the Senographe DS or Senographe Essential introduces a software change that applies different LUT values during the image processing prior to display of a very dense breast, or one with implants. This Premarket Notification will implement this technology on GE Healthcare's existing Full Field Digital Mammography systems as an upgrade to existing systems, or as an option to new installations.
- Intended Use: The Senographe DS and Senographe Essential FFDM systems generate digital mammographic images that can be used for screening and in the diagnosis of breast cancer. The Senographe DS and Senographe Essential FFDM systems are intended to be used in the same clinical applications as traditional film-based mammographic systems.
Premium View is an image-processing algorithm, which increases the visibility of breast structures. The main
{2}------------------------------------------------
Image /page/2/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'G' and 'E' intertwined within a circular border. The letters are stylized and appear to be hand-drawn or calligraphic. The logo is black and white.
advantage is to provide a single breast image, where the contrast in the fatty tissues is similar to that obtained by setting WW (window width) and WL (window level) for optimum visualization of fatty tissues, and the contrast in the fibro-glandular tissue is similar to that obtained by setting WW and WL for optimal visualization of fibroglandular tissues.
PV is an option that can simplify the presentation of mammographic images, improve workflow, and streamline the review process of images with very dark or bright areas by presenting the image with the WW and WL optimized for review with minimal need for the user to make adjustments for the various tissue areas. This could be especially useful with patients who have very dense breasts, or implants that currently require multiple adjustments of WW and WL to review.
Technology: Premium View (PV) is image processing software which further improves the efficiency of the existing autocontrast feature; it also includes a modified version of the existing Tissue Equalization (TE) processing.
Such optimization is achieved by applying different LUTs (Look Up Tables) to a high pass and low pass extractions of the image. In doing so, management of the image dynamic is achieved so that by applying PV it increases the visibility of breast structures. This is done by enhancing the contrast in glandular tissue, while preserving the visibility of the whole breast.
Premium View i, when utilized with the Senographe DS or Senographe Essential introduces a software change that applies different LUT values during the image processing prior to display of a very dense breast, or one with implants.
Determination of Premium View i when installed on a Senographe DS or Substantial Equivalence: Senographe Essential FFDM system delivers functionality of comparable type that is substantially equivalent to our
{3}------------------------------------------------
Image /page/3/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'G' and 'E' intertwined within a circle. The letters are stylized and connected, creating a unique and recognizable design. The logo is black and white.
currently marketed systems listed above and complies with the same or equivalent standards and have the same intended uses.
Summary of Non-Clinical Tests:
The Premium View i option complies with voluntary standards as detailed in Section 9, 11 and 17 of this premarket submission. The following quality assurance measures were applied to the development of the system:
- . Risk Analysis
- . Requirements Reviews
- Design Reviews .
- Testing on unit level (Module verification) .
- . Integration testing (System verification)
- . Performance testing (Verification)
- . Safety testing (Verification)
- . Simulated use testing (Validation)
Summary of Clinical Tests:
The subject of this premarket submission, Premium View i image processing option, included clinical testing to quantify the clinical acceptance of images that had been retrospectively processed with this image processing algorithm.
- Conclusion: GE Healthcare considers the Premium View i option to be as safe, as effective, and performance is substantially equivalent to the predicate device(s).
{4}------------------------------------------------
Image /page/4/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three stylized, curved lines.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20993-0002
Mr. Steven Kachelmeyer, RAC Regulatory Manager GE Healthcare 3000 N. Grandview Blvd Mail Code W-709 WAUKESHA WI 53188
DEC 2 2 2011
Re: K110798
Trade/Device Name: Premium View i (PVi) Regulation Number: 21 CFR 892.1715 Regulation Name: Full-field digital mammography system Regulatory Class: II Product Code: MUE Dated: November 16, 2011 Received: November 17, 2011
Dear Mr. Kachelmeyer:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of
{5}------------------------------------------------
medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely Yours,
Mary Pastel
Mary S. Pastel, Sc.D. Director Division of Radiological Devices Office of In Vitro Diagnostic Device . Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{6}------------------------------------------------
Image /page/6/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'G' and 'E' intertwined in a stylized script, enclosed within a circle. There are decorative swirls or flourishes around the circle, adding to the logo's distinctive appearance.
510(k) Number (if known):
Device Name: Premium View i (PVi)
Indications for Use:
The Senographe DS and Senographe Essential FFDM systems generate digital mammographic images that can be used for screening and in the diagnosis of breast cancer. The Senographe DS and Senographe Essential FFDM systems are intended to be used in the same clinical applications as traditional film-based mammographic systems.
Premium View is an image-processing algorithm, which increases the visibility of breast structures. The main advantage is to provide a single breast image, where the contrast in the fatty tissues is similar to that obtained by setting WW (window width) and WL (window level) for optimum visualization of fatty tissues, and the contrast in the fibroglandular tissue is similar to that obtained by setting WW and WL for optimal visualization of fibro-glandular tissues.
PV i is an option that can simplify the presentation of mammographic images, improve workflow, and streamline the review process of images with very dark or bright areas by presenting the image with the WW and WL optimized for review with minimal need for the user to make adjustments for the various tissue areas. This could be especially useful with patients who have very dense breasts, or implants that currently require multiple adjustments of WW and WL to review.
Prescription Use X AND/OR (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (Part 21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
510(k)
Page 1 of ____________________________________________________________________________________________________________________________________________________________________
§ 892.1715 Full-field digital mammography system.
(a)
Identification. A full-field digital mammography system is a device intended to produce planar digital x-ray images of the entire breast. This generic type of device may include digital mammography acquisition software, full-field digital image receptor, acquisition workstation, automatic exposure control, image processing and reconstruction programs, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II (special controls). The special control for the device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Full-Field Digital Mammography System.”See § 892.1(e) for the availability of this guidance document.